STOCK TITAN

Coeptis Therapeutics Holdings Inc. - COEP STOCK NEWS

Welcome to our dedicated page for Coeptis Therapeutics Holdings news (Ticker: COEP), a resource for investors and traders seeking the latest updates and insights on Coeptis Therapeutics Holdings stock.

Coeptis Therapeutics Holdings Inc is a biopharmaceutical company focused on developing cell therapy platforms for patients with cancer, autoimmune, and infectious diseases. The company's product portfolio includes multi-antigen CAR T technology known as SNAP-CAR, CD38-GEAR-NK cell therapy technology, and CD38-Diagnostic in vitro diagnostic for CD38-related cancers. Coeptis has strategic partnerships with Deverra Therapeutics, VyGen-Bio, the University of Pittsburgh, and the Karolinska Institutet to advance its innovative therapies. With a strong emphasis on research and development, Coeptis aims to revolutionize treatment paradigms and improve patient outcomes across various therapeutic areas.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.98%
Tags
management
-
Rhea-AI Summary
Coeptis Therapeutics announced that research on its SNAP-CAR technology was published in Nature Communications. SNAP-CAR is a multi-antigen CAR T cell technology that can be adapted to different cancer indications. The research highlights advances in antigen receptor design, offering the potential for one population of T cells to target multiple tumor antigens.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.95%
Tags
none
-
Rhea-AI Summary

Coeptis Therapeutics (NASDAQ: COEP) announced a proposed transaction to acquire assets from Deverra Therapeutics, focusing on NK cell therapies for relapsed/refractory acute myeloid leukemia (AML) and respiratory infections. The agreement grants Coeptis exclusive negotiation rights until August 31, 2023, for two IND applications and Phase 1 trials involving NK cell therapy. This acquisition aims to enhance Coeptis' R&D capabilities and diversify its portfolio by integrating a proven allogeneic platform that requires no HLA matching. With anticipated Phase 1 AML trial data expected in 2H 2023, the deal could significantly expand Coeptis' technological footprint. If completed, Deverra's CSO, Dr. Colleen Delaney, is expected to join Coeptis as Chief Scientific and Medical Officer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.15%
Tags
Rhea-AI Summary

Coeptis Therapeutics Holdings (NASDAQ: COEP) has acquired exclusive rights to negotiate for the acquisition of VyGen-Bio, enhancing its oncology pipeline. The GEAR™ Platform and companion diagnostic technologies from VyGen-Bio will support the development of advanced cell therapies targeting CD38+ cancers, including multiple myeloma. Coeptis will initiate due diligence on VyGen-Bio’s assets, focusing on GEAR-NK cell therapy. The companies aim to leverage their collaboration to improve patient outcomes and expand treatment options in immuno-oncology. Successful completion of this transaction could mark a significant growth milestone for Coeptis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.18%
Tags
-
Rhea-AI Summary

Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) announced that its SNAP-CAR technology was featured in a peer-reviewed article in the Journal of Translational Medicine on March 21, 2023. The SNAP-CAR platform, designed for multi-antigen targeting, aims to enhance the efficacy and safety of CAR T therapies for various cancers. The article highlights its potential to overcome limitations of current CAR T technologies by linking antibodies to universal CAR receptors. Coeptis plans to target HER2-expressing ovarian cancer as part of its first-in-human clinical development program, with the technology licensed from the University of Pittsburgh.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
none
-
Rhea-AI Summary

Coeptis Therapeutics (NASDAQ: COEP) has engaged Shareholder Intelligence Services (ShareIntel) for a comprehensive 12-month agreement to monitor and analyze trading patterns of its common stock. This partnership aims to identify illegal short selling and enhance shareholder protections. ShareIntel's DRIL-Down™ technology will track trading anomalies and provide valuable insights into market activities. Coeptis is committed to safeguarding shareholder interests and preventing market manipulation, according to CEO Dave Mehalick. The collaboration is part of Coeptis's broader strategy to protect its stock's value while advancing its cancer treatment platforms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags
none
Rhea-AI Summary

Coeptis Therapeutics has announced a sponsored research agreement with the University of Pittsburgh to advance the pre-clinical development of SNAP-CAR T cells targeting HER2-positive cancers. This collaboration aims to enable the filing of an Investigational New Drug (IND) application for clinical trials involving SNAP-CAR therapies. HER2 is overexpressed in about 28% of ovarian cancer tissues and 25% of breast cancer patients. The research will be led by Dr. Jason Lohmueller and Dr. Alexander Deiters, with the objective of optimizing SNAP-CAR's application in oncology, potentially offering breakthroughs in treatment options for solid tumors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.73%
Tags
none
-
Rhea-AI Summary

Coeptis Therapeutics (NASDAQ: COEP) has announced a strategic collaboration with IQVIA to advance its SNAP-CAR technology, a universal CAR T cell therapy platform. The partnership aims to identify target indications and initiate Investigational New Drug (IND) enabling activities for SNAP-CAR, which can be adapted for various cancer types, including hematologic and solid tumors. Coeptis plans to launch a first-in-human clinical program for SNAP-CAR, emphasizing its potential to treat cancers less accessible with current therapies. The collaboration leverages IQVIA's expertise to streamline the development process.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.17%
Tags
none
-
Rhea-AI Summary

Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) announced that its management will ring the Nasdaq Opening Bell on Nov. 16, 2022. CEO Dave Mehalick expressed excitement about the event, marking the completion of their business combination with Bull Horn Holdings Corp. The company aims to lead in cell therapy technologies for cancer, particularly through their SNAP-CAR platform and a new cell therapy targeting CD38-related cancers. Coeptis is also partnering with VyGen-Bio and researchers at the Karolinska Institutet to develop additional therapies and diagnostics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
none
Rhea-AI Summary

Coeptis Therapeutics (NASDAQ: COEP) announced that its Scientific Advisory Board members, Hans-Gustaf Ljunggren and Evren Alici, participated in the Immuno Oncology Talks podcast discussing Natural Killer (NK) Cells. The company focuses on innovative cancer therapies, significantly featuring the CD38-GEAR-NK platform and CD38-Diagnostic tool, co-developed with VyGen-Bio and Karolinska Institutet. Company President David Mehalick highlighted the expertise of these board members as crucial in advancing Coeptis' commitment to effective cancer treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.13%
Tags
management

FAQ

What is the current stock price of Coeptis Therapeutics Holdings (COEP)?

The current stock price of Coeptis Therapeutics Holdings (COEP) is $0.1415 as of December 20, 2024.

What is the market cap of Coeptis Therapeutics Holdings (COEP)?

The market cap of Coeptis Therapeutics Holdings (COEP) is approximately 5.6M.

What is Coeptis Therapeutics Holdings Inc focused on?

Coeptis is dedicated to developing cell therapy platforms for cancer, autoimmune, and infectious diseases.

What are the key products in Coeptis' portfolio?

The company's product portfolio includes SNAP-CAR multi-antigen CAR T technology, CD38-GEAR-NK cell therapy technology, and CD38-Diagnostic in vitro diagnostic.

Who are some of Coeptis' strategic partners?

Coeptis has strategic partnerships with Deverra Therapeutics, VyGen-Bio, the University of Pittsburgh, and the Karolinska Institutet.

What is Coeptis' goal in their research and development efforts?

Coeptis aims to revolutionize treatment paradigms and improve patient outcomes across various therapeutic areas.

Coeptis Therapeutics Holdings Inc.

Nasdaq:COEP

COEP Rankings

COEP Stock Data

5.64M
31.46M
18.53%
4.28%
0.39%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
WEXFORD